Corneal neovascularization

Current Opinion in Ophthalmology

Volumn 12, Issue 4, 2001, Pages 242-249

  Chang, Jin Hong ^a   Gabison, Eric E ^a   Kato, Takuji ^a   Azar, Dimitri T ^a,b  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^b MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOSTATIN; CALCITRIOL; CURCUMIN; CYCLOSPORIN A; ENDOSTATIN; FIBROBLAST GROWTH FACTOR; INDOMETACIN; MATRIX METALLOPROTEINASE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PIGMENT EPITHELIUM DERIVED FACTOR; PROLACTIN; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEINASE; STEROID; TACROLIMUS; THALIDOMIDE; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARGON PLASMA COAGULATION; CORNEA NEOVASCULARIZATION; DEGENERATION; DISEASE ASSOCIATION; EYE INFECTION; EYE INFLAMMATION; EYE INJURY; HUMAN; NONHUMAN; PATHOGENESIS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; TRANSPLANTATION; VISUAL IMPAIRMENT;

ANGIOSTATINS; ANIMALS; COLLAGEN; CORNEA; CORNEAL NEOVASCULARIZATION; ENDOSTATINS; ENDOTHELIAL GROWTH FACTORS; EYE PROTEINS; FIBROBLAST GROWTH FACTORS; HUMANS; LYMPHOKINES; MATRIX METALLOPROTEINASES; NERVE GROWTH FACTORS; PEPTIDE FRAGMENTS; PLASMINOGEN; PROTEINS; SERPINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034887136     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/00055735-200108000-00002     Document Type: Review

References (102)

1. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization
2. Vascular development: Cellular and molecular regulation
3. Angiogenesis in cancer, vascular, rheumatoid and other disease
4. Experimental corneal neovascularization: Biomicroscopic, angiographic, and morphologic correlation
5. In vivo confocal imaging of corneal neovascularization
6. Corneal neovascularization
7. Angiogenesis in corneal diseases: Histopathologic evaluation of 254 human corneal buttons with neovascularization
8. Ocular neovascularization: An epidemiologic review
9. Hierarchy of prognostic factors for corneal allograft survival
10. Corneal neovascularization after penetrating keratoplasty
11. Long-term follow-up of patients with atopic keratoconjunctivitis
12. Ocular disease pattern induced by herpes simplex virus is genetically determined by a specific region of viral DNA
13. Immunohistochemistry of Terrien's and Mooren's corneal degeneration
14. Ultrastructural features of contact lens-induced deep corneal neovascularization and associated stromal leukocytes
15. An evaluation of the role of leukocytes in the pathogenesis of experimentally induced corneal vascularization. II. Studies on the effect of leukocytic elimination on corneal vascularization
16. An evaluation of the role of leukocytes in the pathogenesis of experimentally induced corneal vascularization
17. An evaluation of the role of leukocytes in the pathogenesis of experimentally induced corneal vascularization. III. Studies related to the vasoproliferative capability of polymorphonuclear leukocytes and lymphocytes
18. Inflammatory Terrien's marginal corneal disease
19. Clinical, secretory and immunologic studies in Terrien disease
20. Histopathologic evaluation of stromal inflammation in Acanthamoeba keratitis
21. Angiogenesis
22. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas
23. Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization
24. Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization
25. A novel alternatively spliced form of murine vascular endothelial growth factor, VEGF 115
26. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization
27. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis
28. Immunohistochemical localization of acidic and basic fibroblast growth factor through corneal neovascularization in vivo and in vitro
29. Binding of basic fibroblast growth factor to normal and neovascularized rabbit cornea
30. The matrix metalloproteinase family
31. Immunolocalization and gene expression of matrilysin during corneal wound healing
32. Matrix metalloproteinases are expressed during wound healing after excimer laser keratectomy
33. Immunoconfocal localization of gelatinase B expressed by migrating intrastromal epithelial cells after deep annular excimer keratectomy
34. Expression of gelatinases A and B, and TIMPs 1 and 2 during corneal wound healing
35. Differential expression of MT1-MMP (MMP-14) and collagenase III (MMP-13) genes in normal and wounded rat corneas
36. Curcuminoids inhibit the angiogenic response stimulated by fibroblast growth factor-2, including expression of matrix metalloproteinase gelatinase B
37. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity
38. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance
39. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice
40. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
41. Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis
42. Recombinant kringle 1-3 of plasminogen inhibits rabbit corneal angiogenesis induced by angiogenin
43. The role of angiostatin in the cornea after wounding
44. Metalloelastase in corneal wound healing, expression, localization and roles
45. Characterization of angiostatin in the mouse cornea
46. Extrahepatic synthesis of plasminogen in the human cornea is up-regulated by interleukins- 1 alpha and -1 beta
47. Diurnal variations in angiostatin in human tear fluid: A possible role in prevention of corneal neovascularization
48. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
49. Collagen XVIII is a basement membrane heparan sulfate proteoglycan
50. Endostatin localization in the cornea
51. Generation and degradation of human endostatin proteins by various proteinases
52. METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity
53. Anti-angiogenic cues from vascular basement membrane collagen
54. Gene expression of the neurotrophic pigment epithelium-derived factor in the human ciliary epithelium: Synthesis and secretion into the aqueous humor
55. Pigment epithelium-derived factor: A potent inhibitor of angiogenesis
56. Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea
57. Inhibition of vascularization in rabbit corneas by heparin: Cortisone pellets
58. Effects of prednisolone and medroxyprogesterone on corneal wound healing, ulceration, and neovascularization
59. Topical formulations of novel angiostatic steroids inhibit rabbit corneal neovascularization
60. Squalamine, a new angiostatic steroid
61. Steroid inhibition of limbal blood and lymphatic vascular cell growth
62. Angiostatic activity of steroids in the chick embryo CAM and rabbit cornea models of neovascularization
63. Regulatory effects of 1 alpha, 25-dihydroxyvitamin D(3) on cytokine production by human corneal epithelial cells
64. Effects of 1 alpha, 25-dihydroxyvitamin D3 on Langerhans cell migration and corneal neovascularization in mice
65. Indomethacin v. dexamethasone in the suppression of corneal neovascularization
66. 2 levels
67. Inhibition of corneal neovascularization in the rat by SK&F 86002, a dual inhibitor of arachidonic acid metabolism
68. Effect of inhibitors of arachidonic acid metabolism on corneal neovascularization in the rat
69. The effect of selective cyclooxygenase-2 inhibitor on corneal angiogenesis in the rat
70. Topical modulation of interleukin-1 activity in corneal neovascularization
71. Effect of octreotide on experimental corneal neovascularization
72. Corneal neovascularization induced by xenografts or chemical cautery: Inhibition by cyclosporin A
73. FK-506 delays corneal graft rejection in a model of corneal xenotransplantation
74. The inhibitory effects of recombinant plasminogen kringle 1-3 on the neovascularization of rabbit cornea induced by angiogenin, bFGF, and VEGF
75. New activity of spironolactone: Inhibition of angiogenesis in vitro and in vivo
76. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization
77. Topical amiloride accelerates healing and delays neovascularization in mechanically produced corneal ulcers in rabbits
78. Curcumin is an in vivo inhibitor of angiogenesis
79. A platelet-activating factor antagonist reduces corneal allograft inflammation and neovascularization
80. Laser photocoagulation for corneal stromal vascularization
81. Laser photocoagulation of experimental corneal stromal vascularization: Efficacy and histopathology
82. Corneal argon laser photocoagulation for neovascularization in penetrating keratoplasty
83. Corneal laser photocoagulation for treatment of neovascularization. Efficacy of 577 nm yellow dye laser
84. Fine needle diathermy occlusion of corneal vessels
85. Photodynamic therapy for corneal neovascularization
86. Photodynamic effect of a new photosensitizer ATX-S10 on corneal neovascularization
87. Photodynamic therapy for corneal neovascularization using topically administered ATX-S10 (Na)
88. Photodynamic effect of a new photosensitizer ATX-S10 on corneal neovascularization
89. Treatment parameters for selective occlusion of experimental corneal neovascularization by photodynamic therapy using a water soluble photosensitizer, ATX-S10(Na)
90. Allograft conjunctival transplantation for bilateral ocular surface disorders
91. Amniotic membrane transplantation with or without limbal allografts for corneal surface reconstruction in patients with limbal stem cell deficiency
92. Identification of antiangiogenic and antiinflammatory proteins in human amniotic membrane
93. Reconstruction of damaged corneas by transplantation of autologous limbal epithelial cells
94. The effects on inhibition of corneal neovascularization after human amniotic membrane transplantation in severely damaged rabbit corneas
95. Inhibition of vascular endothelial cell morphogenesis in cultures by limbal epithelial cells
96. Corneal re-epithelialization from the conjunctiva
97. Induction of conjunctival transdifferentiation on vascularized corneas by photothrombotic occlusion of corneal neovascularization
98. Conjunctival transdifferentiation is due to the incomplete removal of limbal basal epithelium
99. Living related conjunctival limbal allograft for the treatment of stem cell deficiency
100. Human allograft limbal transplantation for corneal surface reconstruction
101. Limbal autograft transplantation for ocular surface disorders
102. Large-diameter lamellar keratoplasty in severe ocular alkali burns: A technique of stem cell transplantation